(1)
DGAP-News: DEBx Medical B.V. / Key word(s): Scientific publication
DEBx Medical publishes first clinical data on novel desiccant gel for chemical debridement of infected, chronic wounds in peer-reviewed journal, Wounds
16.02.2021 / 09:30
DEB
x Medical publishes first clinical data on novel desiccant gel for chemical debridement of infected, chronic wounds in peer-reviewed journal,
Wounds
(R)) removes biofilm and pathogens, enabling the natural healing process to start
[1]
- Case series (n = 10) demonstrated full granulation of wound bed in all patients within 12 weeks after one-time application of desiccant agent
[1]
[1]
[2] with different healing outcomes based on the woundsize and etiology of the wound
[3]
Rotterdam, The Netherlands, February 16, 2021 - DEB
Feb 16 2021 Read 304 Times
Dr Gerard Short, MBBS has joined biotech VarmX, a company focusing on innovative approaches for the reversal of anticoagulation, as Chief Medical Officer (CMO). He will be responsible for overseeing the clinical development of the company’s pipeline, including progression of its lead product, VMX-C001, into clinical proof of concept and registrational studies.
With more than 20 years working with both big pharma and biotechs, Dr Short’s clinical development expertise has a particular focus on rare diseases and gene therapy for haematological disorders. He joins VarmX from Freeline Therapeutics, where he served for five years as SVP Clinical and Regulatory and later SVP Medical Science, establishing an in-house pharmacovigilance function and advancing gene therapy clinical programmes in haemophilia B and Fabry’s disease. During a decade at Genzyme, he led the Global Development Team treatment programmes targeting Pompe’s disease (phase 3) and acut
(1)
SEATTLE, Feb. 16, 2021 /PRNewswire/ LumiThera Inc., a commercial stage medical device company offering a photobiomodulation (PBM) treatment for ocular damage and disease, today announced the interim data from the ELECTROLIGHT pilot study in dry AMD patients.
A total of 23 eyes from 15 subjects with intermediate Dry AMD were enrolled into the prospective clinical study and treated with PBM using the Valeda Light Delivery System (3 times per week for 3 weeks). Subjects were tested for safety and functional vision improvements using the Diopsys electroretinogram (ERG) device. ERG is a diagnostic test that measures the electrical activity of the retina of the eye in response to a light stimulus. All subjects were tested at weekly intervals for ERG function prior to the start of the next week of PBM treatments. An interim analysis was performed following the Month 1 study visit. The study was conducted by Dan Montzka, M.D. and Larry Perich, D.O. at the Perich Eye Center (New Por
Skip to main content
Shelton s Echo Hose seek to take over paramedic service in 2022, will save Medicare patient costs
Brian Gioiele
FacebookTwitterEmail
Echo Hose Ambulance and Valley Emergency Medical Services late last week reached an agreement making Echo Hose the primary paramedic service for Shelton beginning in January 2022.Echo Hose Ambulance / Contributed photo
SHELTON Echo Hose Ambulance is closer to being the city’s primary paramedic service, a move ambulance officials say will mean lower costs for Medicare patients.
Echo Hose Ambulance and Valley Emergency Medical Services late last week reached an agreement making Echo Hose the primary paramedic service for the city beginning in January 2022.
(1)
Median is building a cloud based end-to-end approach performing both localization and discrimination of malignant and benign lung lesions.
The company plans to demonstrate the potential of deep learning models to increase the accuracy, consistency and adoption of lung cancer screening worldwide.
First results for a proof of concept on a cohort of 1,800 patients are expected in H2, 2021.
Regulatory News:
Median Technologies (ALMDT:PA) (Paris:ALMDT) unveils today a new iBiopsy Clinical Development Plan (CDP) for the diagnosis of early-stage lung cancer in high-risk populations based on Low Dose Computed Tomography (LDCT) scans, strengthening its positioning in early-stage diagnosis, such as early-stage liver cancer diagnosis and non-alcoholic steatohepatitis (NASH) identification.